After several postponed decisions, Mylan Inc (MYL) has announced that it is moving forward with a Botox biosimilar development program in collaboration with …
AbbVie (ABBV) announced on Monday that it has entered into a partnership with Jacobio Pharmaceuticals, to jointly develop and commercialize SHP2 inhibitors, which target a …
AbbVie’s (ABBV) acquisition of Allergan has entered the final stretch, after the FTC (federal trading commission) gave its consent for the deal to …
AbbVie’s (ABBV) plan to close the $63 billion Allergan (AGN) deal this month appears on track following the announcement that they have received …
Worth $23 billion today, former math professor Jim Simons has become one of the most successful money managers of all time. Following his …
Investors have voted with their wallets, and the verdict is in: they want income and growth. That shouldn’t be surprising, as income and …
By Amber Hestla This past weekend, I had a chance to talk to a friend who’s been trading financial markets for more than …
Alex Arfaei notes he continues to be the “lone bear” on this biotech player- especially after lead pipeline asset Rova-T is no longer looking at quick approval.
by Bob Ciura Pharmaceutical companies are among the strongest dividend growth stocks in the market. For example, Gilead Sciences, Inc.
Analysts are weighing in today on healthcare giants Gilead Sciences, Inc. (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV).
